肿瘤预防与治疗2025，Vol.38Issue(10)：911-917,7.DOI:10.3969/j.issn.1674-0904.2025.10.009
三阴性乳腺癌免疫治疗的进展
Advances in Immunotherapy for Triple-negative Breast Cancer
摘要
Abstract
Breast cancer ranks first in both incidence and mortality rates among women.Triple-negative breast cancer(TNBC)is a subtype of breast cancer characterized by the absence of estrogen receptor,progesterone receptor,and human epi-dermal growth factor receptor 2 expression.TNBC is unresponsive to endocrine and targeted therapies and is highly aggressive with a tendency to recur and metastasize.Thus,identifying effective treatments is crucial to improving patient outcomes.Immu-notherapy has now demonstrated notable efficacy in TNBC,presenting a new hope for significantly improving patient outcomes.This article reviews recent advances in immunotherapy for TNBC,aiming to inform and guide treatment strategies for patients.关键词
三阴性乳腺癌/免疫治疗/预后/乳腺癌Key words
Triple-negative breast cancer/Immunotherapy/Prognosis/Breast cancer分类
医药卫生引用本文复制引用
周凤蓝,洪煌明..三阴性乳腺癌免疫治疗的进展[J].肿瘤预防与治疗,2025,38(10):911-917,7.基金项目
This study was supported by National Natural Science Foundation of China(No.82270198,No.82003196),and by grants from Science and Technology Department of Sichuan Province(No.2022JDJQ0059)and Sichuan Cancer Hospital(No.2021 Clinical Scientist Program).国家自然科学基金(编号:82270198、82003196) （No.82270198,No.82003196）
四川省科技计划杰出青年科技人才(编号:2022JDJQ0059) （编号:2022JDJQ0059）
四川省肿瘤医院临床科学家计划(编号:2021年度临床科学家计划) （编号:2021年度临床科学家计划）
